Overview
Pharmacokinetics of Dexmedetomidine in Morbid Obesity
Status:
Unknown status
Unknown status
Trial end date:
2015-07-01
2015-07-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Dexmedetomidine hydrochloride ,a relatively new drug in Chinais ,is a highly selective, potent a2-adrenoceptor agonist with significant analgesic, sedative and anxiolytic effects. The morbid obesity in Chinese population is rapidly increasing. But the pharmacokinetics of the drug in these people is still unknown.This research was designed to study the pharmacokinetics of dexmedetomidine in Chinese morbidly obese population.Phase:
Phase 4Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Guangzhou General Hospital of Guangzhou Military CommandTreatments:
Dexmedetomidine
Criteria
Inclusion Criteria:1. Weight:28≦BMI≦45 and 18.5≦BMI≦24
2. Written informed consent from the patient or the relatives of the participating
patient.
Exclusion Criteria:
1. A previous history of intolerance to the study drug or related compounds and
additives.
2. Existing significant haematological, endocrine, metabolic or gastrointestinal disease.